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BACKGROUND: The use of sentinel node biopsy (SNB), lymph node dissection, breast-conserving surgery, radiotherapy, chemotherapy
and hormonal treatment for breast cancer was evaluated in relation to socioeconomic status (SES) in the Netherlands, where access
to care was assumed to be equal.
METHODS: Female breast cancer patients diagnosed between 1994 and 2008 were selected from the nationwide population-based
Netherlands Cancer Registry (N¼ 176 505). Socioeconomic status was assessed based on income, employment and education at
postal code level. Multivariable models included age, year of diagnosis and stage.
RESULTS: Sentinal node biopsy was less often applied in high-SES patients (multivariable analyses, p49 years: odds ratio (OR) 0.70
(95% CI: 0.56–0.89); 50–75 years: 0.85 (0.73–0.99)). Additionally, lymph node dissection was less common in low-SES patients aged
X76 years (OR 1.34 (0.95–1.89)). Socioeconomic status-related differences in treatment were only significant in the age group
50–75 years. High-SES women with stage T1–2 were more likely to undergo breast-conserving surgery (þ radiotherapy) (OR 1.15
(1.09–1.22) and OR 1.16 (1.09–1.22), respectively). Chemotherapy use among node-positive patients was higher in the high-SES
group, but was not significant in multivariable analysis. Hormonal therapy was not related to SES.
CONCLUSION: Small but significant differences were observed in the use of SNB, lymph node dissection and breast-conserving surgery
according to SES in Dutch breast cancer patients despite assumed equal access to health care.
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Breast cancer is the most common cancer in females from
Western countries, particularly in Western Europe (Ferlay et al,
2010). Incidence rates are generally highest among women with
high socioeconomic status (SES) (Faggiano et al, 1997;
Carlsen et al, 2008; National Cancer Intelligence Network, 2009;
Spadea et al, 2009). However, at least for the Netherlands, we
observed age-specific differences in this association. In women
aged 25–44 years, the highest incidence rates were reported for
those with high SES, whereas in those aged X65 years rates were
the lowest for those with a high SES. No socioeconomic inequal-
ities were observed in those aged 45–64 years (Aarts et al, 2010).
Survival from breast cancer has been reported to be generally
worse in those with low SES (Schrijvers et al, 1995; Bastiaannet
et al, 2011), although better survival rates have been observed by
others (Faggiano et al, 1997). In the Netherlands, an equal health-
care system is provided and a health insurance is compulsory for
all inhabitants. However, survival disparities from breast cancer
have been reported. These were partly explained by tumour size
(Bastiaannet et al, 2011) and by stage differences resulting from
differences in attendance to the free population screening
programme (Aarts et al, 2011).
Treatment disparities were present in studies from Denmark
and the UK, which have shown that deprived women had higher
mastectomy rates, although the odds of receiving radiotherapy
after breast-conserving surgery was not associated with SES as well
as chemotherapy and endocrine treatment (Norredam et al, 1998;
Taylor and Cheng, 2003; Henley et al, 2005; Downing et al, 2007;
Raine et al, 2010). Furthermore, the use of sentinel node biopsy
(SNB) was higher in regions with a high educational level in the US
(Halpern et al, 2009), but to our knowledge this has not been
studied in other countries.
Although Dutch health care is supposedly equally accessible,
socioeconomic treatment disparities were reported for colon,
pancreas, prostate and oesophageal cancer (Aarts et al, submitted;
Lemmens et al, 2005; van Oost et al, 2006; Bus et al, 2012).
However, for breast cancer care it is not known whether there
are differences in axillary staging and treatment. Therefore, we
investigated the association between SES and the use of SNB,
lymph node dissection, breast-conserving surgery, radiotherapy,
chemotherapy and hormonal treatment for breast cancer in the
Netherlands.
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Female patients with their first primary breast cancer (invasive and
in situ) diagnosed between 1994 and 2008 were selected from the
Netherlands Cancer Registry. Patients with other tumours before
their breast cancer were excluded. The nationwide Dutch network
and registry of histopathology and cytopathology regularly
submits reports of all diagnosed malignancies to the regional
cancer registries. The national hospital discharge databank, which
receives discharge diagnoses of admitted patients from all Dutch
hospitals, completes case ascertainment. After notification, trained
registry personnel collect data on diagnosis, staging and treatment
from the medical records, including pathology and surgery
reports, about 9 months after diagnosis, using the registration
and coding manual of the Dutch Association of Comprehensive
Cancer Centres.
Stage was divided according to TNM classification at the year of
diagnosis. Pathological T, N and M stage was used; clinical stage
was used if pathological was missing.
In the Netherlands, the SNB was gradually implemented from
1998 to 2003; we therefore studied the SNB from 2003 onwards.
It is registered in six of nine regional registries; analyses on SNB
were limited to these registries and to stage cT1,2N0M0,X.
National guidelines for treatment of breast cancer were
introduced in the Netherlands in 2002 (Working Group
Treatment Breast Cancer, 2002). Before that time, treatment was
based on regional guidelines. Treatment was categorised as breast-
conserving surgery, external beam radiotherapy after breast-
conserving surgery, chemotherapy and hormonal therapy. The
use of breast-conserving surgery and breast-conserving surgery
plus external beam radiotherapy was studied among patients with
stage T1,2N0M0,X breast cancer and chemotherapy and hormonal
therapy in TanyNþM0,X breast cancer. The use of chemotherapy
was studied from 2002 onwards, as treatment guidelines were
rapidly changing before that time. The use strongly increased from
1994 to 2002 and gradually further increased afterwards. We were
not able to classify chemotherapy as adjuvant or neoadjuvant.
The population-based screening programme for breast
cancer in the Netherlands started around 1990 and covered in
1997 all women aged 50–69 years; in 1998 the upper age limit was
extended to 75.
Socioeconomic status
Socioeconomic status was assigned to each patient using an area-
based measure according to place of residence at the time of
diagnosis. The area-based SES was provided by the Netherlands
Institute for Social Research and consists of numbers from income,
employment and education, which are provided to the institute by
a private organisation that collects information by telephone calls
with one person per 6-digit postal code area; this person is seen
as representative for his or her area. Next, numbers are aggregated
to 4-digit postal code areas. Validation studies indicate that these
numbers at aggregated level approach the true situation (Tesser
et al, 1995). A higher score represents a high social deprivation
(low SES) and a low score represents little social deprivation and
consequently a high SES. Scores were divided into quintiles.
Statistical analysis
All statistical tests were two-sided and were considered significant
if Pp0.05. The distribution of sociodemographic and clinical
characteristics was studied across the SES strata. Significance
was tested with non-parametric tests (continuous variables) and
w2-tests (categorical variables).
Analyses were stratified according to the age groups p49,
50–75, X76. The odds ratios (OR) were stratified by these age
categories and adjusted for age (continuously), year of diagnosis,
SES and T-stage. After excluding patients with unknown SES
(N¼ 445) and non-carcinomas (N¼ 1548), data on 176 505
patients were analysed.
RESULTS
Patients with highest SES were on average 3 years younger
(Po0.0001) and had a lower stage of disease than patients with the
lowest SES (Po0.001; Table 1).
The use of the SNB procedure for stage cT1,2N0M0,X breast
cancer increased from 74% in 2003 to 88% in 2008. In general,
Table 1 Patient characteristics of breast cancer patients in the Netherlands, diagnosed during 1994–2008
Socioeconomic status
5. lowest 4. 3. intermediate 2. 1. highest
N % N % N % N % N %
Period of diagnosis
1994–1998 10 234 23 10 296 18 10 413 20 9372 20 11 689 20
1999–2003 11 990 20 11 616 21 11 580 19 12 695 19 11 845 20
2004–2008 13 077 18 13 389 20 13 308 21 13 234 21 11 767 20
Age at diagnosis*,#
Mean 62.2 61.4 60.7 59.9 59.3
0–49 7673 22 8003 23 8477 24 9128 26 10 101 29
50–75 20 823 59 21 314 60 21 339 60 21 104 60 20 058 57
76þ 6805 19 5984 17 5485 16 5069 14 5142 15
TNM stage*
0 (in situ) 2755 8 2934 8 3100 9 3081 9 3150 9
1 11 964 34 12 203 35 12 384 35 12 636 36 12 561 36
2 14 686 42 14 682 42 14 402 41 14 437 41 14 566 41
3 3601 10 3450 10 3434 10 3271 9 3144 9
4 1899 5 1644 5 1601 5 1541 4 1425 4
Unknown 396 1 388 1 380 1 335 1 455 1
Abbreviation: TNM¼ tumour–node–metastasis. *Po0.0001 (w2-test). #Po0.0001 (t-test).
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high-SES patients less often received SNB, with 1–3% lower rates in
high- vs low-SES patients agedp75, but not statistically significant
(Table 2). These differences were significant in multivariable
analyses (age p49: OR 0.70 (95% CI: 0.56–0.89); 50–75 years: 0.85
(0.73–0.99)). In the oldest age group no consistent pattern on the
use of SNB appeared. Compared with high SES, rates of lymph
node dissection in addition to SNB were slightly higher in low-SES
patients in the youngest age group (36% vs 39%, not statistically
significant), and lower in low-SES patients in the oldest group
(27% in high SES vs 22% in low SES, P¼ 0.01). In multivariable
Table 2 The use of the sentinel node procedure and additional lymph node dissection for breast cancer patients in the Netherlands, diagnosed
2003–2008, stage cT1,2N0M0,X
Sentinel node biopsy
Lymph node dissection in patients with
sentinel node biopsy
Age (years) Socioeconomic status Ntotal % SNB P-value OR 95% CI Trend % LND P-value OR 95% CI Trend
p49 1. Highest 1262 84.0 0.1 0.70 0.56 0.89 0.053 36.4 0.7 0.90 0.76 1.08 0.7
2. 1305 85.4 0.80 0.63 1.02 36.6 0.91 0.76 1.08
3. Intermediate 1401 85.9 0.84 0.66 1.06 36.4 0.90 0.75 1.07
4. 1431 86.2 0.87 0.69 1.11 37.1 0.91 0.76 1.08
5. Lowest 1173 87.8 1.00 38.9 1.00
50–75 1. Highest 2635 87.2 0.2 0.85 0.73 0.99 0.2 28.2 0.6 0.94 0.84 1.06 0.6
2. 3405 87.6 0.90 0.77 1.04 30.3 1.03 0.93 1.16
3. Intermediate 3832 88.9 0.97 0.84 1.12 29.6 1.03 0.93 1.15
4. 4209 88.3 0.96 0.84 1.11 29.0 0.99 0.89 1.10
5. Lowest 3613 88.5 1.00 29.2 1.00
X76 1. Highest 506 53.2 0.1 1.01 0.80 1.28 0.06 27.1 0.01 1.34 0.95 1.89 0.01
2. 668 46.1 0.79 0.64 0.98 30.2 1.55 1.11 2.14
3. Intermediate 793 52.7 1.10 0.90 1.36 31.1 1.64 1.21 2.21
4. 1008 49.8 0.94 0.77 1.14 29.3 1.51 1.13 2.01
5. Lowest 966 50.9 1.00 21.5 1.00
Abbreviations: 95% CI¼ 95% confidence interval; LND¼ lymph node dissection; OR¼ odds ratio, adjusted for age, year of diagnosis, T-stage and histology; SNB¼ sentinel node
biopsy. P-values are from w2 test. Trend refers to P-value from trend test.
Table 3 Use of therapies for breast cancer in the Netherlands according to socioeconomic status, diagnosed during 1994–2008
Age at diagnosis
p49 50–75 X76
% P-value OR 95% CI Trend % P-value OR 95% CI Trend % P-value OR 95% CI Trend
Breast-conserving surgery, T1,2N0M0,Xa
1. Highest SES 60.9 0.8 0.95 0.86 1.04 0.7 64.1 o0.0001 1.15 1.09 1.22 o0.0001 24.0 0.02 1.21 1.06 1.38 0.02
2. 61.2 0.97 0.88 1.07 63.8 1.09 1.03 1.16 22.6 1.10 0.96 1.26
3. Intermediate 60.6 0.95 0.86 1.05 62.3 1.04 0.99 1.10 20.8 0.98 0.86 1.13
4. 60.2 0.94 0.85 1.03 61.8 1.03 0.98 1.09 21.5 1.04 0.91 1.19
5. Lowest SES 61.5 1.00 60.4 1.00 20.6 1.00
Breast-conserving surgeryþ radiotherapy, T1,2N0M0,Xa
1. Highest SES 58.9 0.8 0.96 0.87 1.05 0.8 62.3 o0.0001 1.16 1.09 1.22 o0.0001 18.3 0.5 1.10 0.95 1.28 0.5
2. 59.6 0.99 0.90 1.09 61.9 1.10 1.04 1.16 17.8 1.05 0.90 1.22
3. Intermediate 59.1 0.97 0.88 1.07 60.5 1.05 0.99 1.11 16.6 0.96 0.83 1.11
4. 58.3 0.95 0.86 1.05 60.0 1.04 0.99 1.10 17.1 1.02 0.88 1.17
5. Lowest SES 59.3 1.00 58.4 1.00 16.7 1.00
Hormonal therapy, TanyNþM0,Xb
1. Highest SES 48.3 0.3 1.08 0.98 1.20 0.2 71.5 0.9 1.02 0.94 1.10 0.9 79.8 0.2 0.93 0.79 1.11 0.2
2. 50.4 1.11 1.00 1.23 71.3 1.01 0.93 1.09 78.9 0.93 0.79 1.10
3. Intermediate 48.4 1.01 0.91 1.12 71.7 1.00 0.93 1.08 81.0 1.04 0.88 1.22
4. 48.4 1.02 0.91 1.13 71.5 0.98 0.90 1.06 77.9 0.87 0.74 1.01
5. Lowest SES 49.3 1.00 72.1 1.00 80.3 1.00
Chemotherapy, TanyNþM0,Xc
1. Highest SES 93.2 0.3 0.95 0.73 1.24 0.3 61.7 o0.0001 1.11 0.98 1.26 0.5 2.4 0.2 1.08 0.56 2.09 0.1
2. 93.3 0.97 0.75 1.27 58.8 1.03 0.91 1.17 1.3 0.45 0.22 0.91
3. Intermediate 94.1 1.10 0.83 1.45 57.2 1.01 0.89 1.14 1.9 0.62 0.32 1.19
4. 92.4 0.83 0.63 1.08 56.1 1.02 0.90 1.15 1.8 0.67 0.36 1.25
5. Lowest SES 93.8 1.00 55.3 1.00 2.9 1.00
Abbreviations: 95% CI¼ 95% confidence interval; OR¼ odds ratio; SES¼ socioeconomic status. P-value refers to w2-test. Trend refers to P-value for trend. aOR adjusted for age
(continuously), year of diagnosis, T-stage (T2N0 vs T1N0). bOR adjusted for age (continuously), year of diagnosis, T-stage (T2Nþ , T3Nþ , T4Nþ vs T1Nþ ). cFrom 2002
onwards. OR adjusted for age (continuously), year of diagnosis, T-stage (T1Nþ , T3Nþ , T4Nþ vs T2Nþ ).
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analyses, among the patients aged X76 receiving SNB, those with
high SES more often received lymph node dissection compared
with those with low SES, although not statistically significant for
the highest SES group (OR 1.34 (95% CI: 0.95–1.89)).
Small, statistically significant socioeconomic differences were
present in treatment selection in those aged 50–75 years. The use
of breast-conserving surgery was slightly higher in high-SES
patients (stage T1,2N0M0,X), i.e. 64% of patients with high SES
compared with 60% of those with low SES (w2-test Po0.0001;
Table 3). Nearly all of these patients received additional
radiotherapy (97%), which was not significantly different between
the SES groups. In multivariable analyses, the odds of breast-
conserving surgery remained significantly increased (OR 1.15
(95% CI: 1.09–1.22) for high vs low SES), also for breast-conserving
surgery plus radiotherapy (OR 1.16 (95% CI: 1.09–1.22); Table 3).
In this early stage, an inverse association was observed for
mastectomy, with lower rates in high-SES women aged 50–75 years
(data not shown).
In those aged 50–75 years, the use of endocrine treatment was
not related to SES, neither in univariable nor in multivariable
analyses (Table 3). Rates of chemotherapy for node-positive breast
cancer were highest in high-SES patients (62% vs 55% in low SES,
w2-test Po0.0001), but were no longer significant in multivariable
analyses (Table 3).
Of all therapies mentioned above, none was significantly related
to SES in women agedo50 years. In women of ageX76 years, the
only significant associations were observed for breast-conserving
surgery, with higher rates in the high-SES group (w2-test P¼ 0.02,
OR high vs low SES 1.21 (95% CI: 1.06–1.38)), and for
chemotherapy, in which rates were reduced in the second highest
SES group (OR 0.45 (95% CI: 0.22–0.91). The use of breast-
conserving surgery and radiotherapy combined, however, was not
significantly related to SES (OR 1.10 (95% CI: 0.95–1.28)).
DISCUSSION
This study shows that in the Netherlands, a country with assumed
equal access to care, breast cancer patients with high SES were less
likely to undergo SNB and, in the oldest group, more likely
to receive additionally lymph node dissection. Furthermore, in
patients aged 50–75 years the use of breast-conserving surgery and
chemotherapy was significantly related to SES, although the
absolute differences between the SES groups were generally small.
In early-stage breast cancer, the use of breast-conserving surgery
(þ radiotherapy) was the highest in patients with high SES.
This could not be fully explained by patient age, year of diagnosis
and T-stage. Among the patients with node-positive breast cancer,
a higher use of chemotherapy was observed among those with high
SES. This difference, however, disappeared after adjustment for
stage, age and year of diagnosis.
A prior US study showed higher rates of lymph node biopsy/
sampling, that is, either axillary lymph node dissection or SNB, in
areas where the education level was higher, although the absolute
differences were small (Halpern et al, 2009). Our data suggest a
poorer staging of the axillary lymph nodes and abandoning
surgery in the armpit in patients with high SES. We cannot explain
this observation as we expected the rates to increase with higher
SES owing to — among others — better understanding of the
importance of axillary staging. Possibly, patients with high SES are
more conscious of the side effects of lymph node dissection, such
as lymph oedema, and therefore are more inclined not to undergo
this therapy. Previously, older age was associated with reduced
likelihood of receiving lymph node biopsy (Halpern et al, 2009),
but the mean age differed by only 3 years in our study, suggesting
that age only little affected the staging procedure. Another study
stated that among women undergoing breast-conserving surgery,
those with comorbid conditions were less likely to receive axillary
dissection (Louwman et al, 2005). As cancer patients with high SES
have fewer comorbidities (Louwman et al, 2010), higher rates of
axillary dissection would be expected among high-SES patients.
We had no information on comorbidities in this study, but it
probably has not contributed to the lower rates of SNB in high-SES
patients in our study population. Besides, in the US, patients
treated in hospitals with higher patient volumes were more likely
to receive lymph node biopsy (Halpern et al, 2009). Possibly this
has affected our results as well. Also, in the Netherlands, staging
procedures and type of surgery depended on hospital character-
istics, such as volume, with reducing differences over time (van
Steenbergen et al, 2010). It should be noted, however, that absolute
differences in our study were small and that statistical significance
may have resulted from the large number of patients.
Our results on treatment selection are in line with and the order
of magnitude is fairly similar to studies from Denmark and the UK.
These studies have shown that women with a lower SES had higher
mastectomy rates (Norredam et al, 1998; Taylor and Cheng, 2003;
Henley et al, 2005) and lower breast-conserving surgery rates
(Taylor and Cheng, 2003; Downing et al, 2007; Raine et al, 2010),
although an age-dependent association has been observed as well
(Thomson et al, 2001). Adjustment for stage explained the higher
mastectomy rates observed in low SES (Henley et al, 2005),
whereas the association remained significant after stratification by
tumour size (Taylor and Cheng, 2003) and stage (our study, early
stage (data not shown)). This implies that type of surgery chosen
for the SES groups is not fully explained by stage and age in early-
stage disease. Because of higher prevalence of concomitant
diseases in patients with low SES (Louwman et al, 2010), type of
surgery is expected to be less invasive owing to the poor general
condition in low SES patients. In fact, we observed higher invasive
surgery (mastectomy) rates in low SES. Presence of comorbidities
might also be indicative of mastectomy to avoid the effects of
radiotherapy, but this has not been studied before. A Northern
Italian study found that presence of comorbidities reduced the
odds of receiving radiotherapy after breast-conserving surgery
(Rosato et al, 2009). Besides, that study also reported no
educational differences in treatment of early-stage breast cancer
after adjustment for comorbidities and hospital characteristics
(Rosato et al, 2009). As discussed previously, hospital
characteristics were affecting treatment selection, including type
of surgery and use of radiotherapy, in the Netherlands as well
(Vulto et al, 2005; Siesling et al, 2007; van Steenbergen et al, 2010),
but we could not take these into account in our analyses.
Nor were we able to investigate the contributions of ER status or
grade, but previously these factors were reported to be not
associated to SES (Henley et al, 2005). More active involvement of
the patient in decision making led to higher mastectomy rates
(Katz et al, 2005), but the effects in the Netherlands remain
to be studied.
In our study, in accordance with the Dutch treatment guidelines
(Oncoline. www.oncoline.nl.), nearly all patients undergoing
breast-conserving surgery received additional radiotherapy (97%)
and no differences were observed between the SES groups. Our
results are in line with a study from the UK, in which the odds of
receiving adjuvant radiotherapy was not associated with depriva-
tion (Downing et al, 2007). Compared with the US, our rates of
adjuvant radiotherapy are high (97% vs 73%) (Smith et al, 2010).
Furthermore, in the US, large SES differences were observed, with
adjuvant radiotherapy rates of 67% in patients with low SES vs 78%
in those with high SES in the period 1991–2002, which were not
explained by stage, hormone receptor status, grade, chemotherapy,
comorbidity and surgeon characteristics (Hershman et al, 2008).
Similar differences were observed in another US study investigat-
ing adjuvant radiotherapy rates according to race, which reported
74% in whites vs 65% in blacks (Smith et al, 2010), which remained
also significant after adjustment for demographic, clinical
(including comorbidities) and socioeconomic covariates.
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Previous studies have reported inconsistent results with respect
to the associations between SES and adjuvant radiotherapy,
chemotherapy and endocrine treatment (Macleod et al, 2000;
Taylor and Cheng, 2003; Downing et al, 2007), with higher rates in
high SES in some studies but no association in others (Macleod
et al, 2000; Downing et al, 2007; Bhargava and Du, 2009). Low
educational level was associated with reduced doses of chemo-
therapy, whereas presence of comorbidities was not associated
(Griggs et al, 2007). No data were available on chemotherapy doses
from the Netherlands Cancer Registry. Besides, we have used the
pathological staging supplemented with clinical TNM in case
postoperative data were missing. As we were not able to classify
chemotherapy as adjuvant or neoadjuvant, the staging may not be
completely correct for the patients who received neoadjuvant
chemotherapy.
Higher education predicted hormonal therapy use in older US
breast cancer survivors (Yen et al, 2011). For those on hormonal
therapy, wealthier women and women with insurance coverage for
some or all medication costs were more likely to receive an
aromatase inhibitor, which is prescribed by the American Society
for Clinical Oncology (ASCO) (Yen et al, 2011). Owing to the
Dutch obligatory health insurance for every inhabitant, insurance
status is unlikely to affect treatment selection. This is in line with
our finding that hormonal therapy was not related to SES in our
study.
Unfortunately, patient preferences in itself could not be taken
into account in this study. For example, the choice of mastectomy
depends on the interplay between the surgeon’s recommendations
and patients’ preferences for treatment (Hawley, 2010). The role of
patient decision making (Smith et al, 2009) is likely to be
influenced by health literacy, that is, ‘The degree to which
individuals have the capacity to obtain, process, and understand
basic health information and services needed to make appropriate
health decisions’ (National Network of Libraries of Medicine,
2010). Low health literacy may lead to treatment options that are
not fully understood, and therefore some patients may not receive
the most appropriate treatment for their medical condition
(Merriman et al, 2002). As SES can be linked with education,
those with low SES are expected to be more vulnerable to low
health literacy. A solution towards solving this might be to focus
more on clear and adapted communication by health-care
providers. In contrast, some patients do not want to be very
involved in decision making (Lantz et al, 2005; Levinson et al,
2005).
Our study findings might be influenced by several limitations.
First, we had no information on the presence of comorbidities,
which may have affected therapy selection. Second, data on grade,
ER status and PR status were not available, which might have
affected our results. Third, we had no information on hospital
characteristics, which affected therapy selection in Italy and the
Netherlands; however, in the latter study, regional and hospital
variation reduced over time (Rosato et al, 2009; van Steenbergen
et al, 2010). Fourth, in this study we have used a measure of SES
based on 6-digit postal code of the residential area. Our results
may therefore be subject to ecological fallacy. Furthermore, our
findings may be explained by some residual confounding.
Although this measure of SES is not based on individual data on
income, education or occupation, it covers a relatively small
geographical area and thus is likely to represent a reliable
approximation of individual SES. Previous studies in the Nether-
lands have proven that socioeconomic differences based on
neighbourhood data tend to reflect socioeconomic differences
accurately at the individual level (Bos et al, 2000, 2001; Smits et al,
2001). Furthermore, as the measure of SES used in this study is
based on several outcomes, it also applies to older women (born
before 1955), although their occupation or education does not
always properly reflect their social class (Berkman and Macintyre,
1997).
Nevertheless, we have used population-based nationwide data,
including all breast cancer patients from the Netherlands. We have
thus provided a complete overview of the association between SES
and the staging and treatment selection of breast cancer, which has
not been done before.
CONCLUSION
Small but significant differences were observed in the use of SNB,
lymph node dissection and breast-conserving surgery according to
SES in Dutch breast cancer patients despite the assumed equal
access to health care.
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